Key Highlights
- Oxford BioDynamics secured its first paying customer for EpiSwitch Orion, a UK academic and NHS consortium running the OPTIMISE study.
- A US contract sales Partnership with MK Commercial Group will deploy up to 35 field representatives for EpiSwitch PSE.
- H1 Revenue to 31 March 2026 rose 17% to £687,000, with the operating loss narrowing to £4.68 million from £5.88 million.
- Cash fell to £1.38 million by 31 May 2026, with the board stating a need for additional funds by late August 2026.
- Richard Compton, formerly of Oxford Nanopore Technologies, was named new chief executive.
The AIM-listed epigenetics group has signed its first commercial agreement for the EpiSwitch Orion data platform and landed a US sales partnership, but interim results reveal cash of just £1.38m and a stated need for fresh funds by late August 2026.
Oxford BioDynamics (LSE:OBD), the Oxford-based epigenetics diagnostics company behind the EpiSwitch blood-test platform, has spent the summer trying to prove its technology can pay its own way. On 28 July 2026 it announced the first-ever paid third-party use of EpiSwitch Orion, its data-processing platform, followed weeks earlier by a US contract sales tie-up for its EpiSwitch PSE prostate test. Both are genuine commercial milestones for a company that has long promised more revenue than it has delivered. But they arrive alongside interim results that lay out, in unusually blunt terms, a cash position the board says will need topping up within weeks.
What Happened
The 28 July RNS confirmed that EpiSwitch Orion — the platform OBD uses to process whole-genome epigenetic data into biomarker signatures — has secured its first paying customer since launch. The counterparty is not a single company called "Orion" but a UK academic and NHS consortium running the OPTIMISE study into psoriatic arthritis therapy, comprising Oxford University's Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, the University of Glasgow, King's College London and Guy's and St Thomas' NHS Foundation Trust, funded by the Department of Health and Social Care via the National Institute for Health and Care Research. OBD will be paid for wet-lab biomarker discovery work and for genomic data processing on Orion. Financial terms were not disclosed.
That followed a 30 June announcement of a US contract sales partnership with MK Commercial Group, under which up to 35 field-based specialist representatives — an initial seven — will promote EpiSwitch PSE to urologists and GPs in New Jersey, Washington DC, Virginia, Georgia and the Chicago area, under OBD's commercial direction. The same day, OBD named Richard Compton, formerly senior vice-president of sales at Oxford Nanopore Technologies, as chief executive, with outgoing executive chairman Iain Ross moving to non-executive chairman.
Why It Matters
For a company that has spent years explaining why revenue has lagged its technology's promise, actual paid usage of Orion — and a scalable, lower-fixed-cost US sales channel — are meaningful proof points, suggesting a strategy shift under new Leadership toward asset-light deals rather than OBD funding its own sales infrastructure. Investors have been here before, though: prior partnership announcements have repeatedly failed to translate quickly into material revenue, so the size and durability of these arrangements will matter more than their existence.
Latest Financial and Operational Performance
Interim results for the six months to 31 March 2026, published on 30 June 2026, showed revenue of £687,000, up from £587,000 a year earlier — a 17% increase, still derived predominantly from EpiSwitch PSE clinical test sales. The operating loss narrowed to £4.68m from £5.88m, and the loss for the period was £4.464m against £5.751m a year earlier, with loss per share of 0.1p (H1 2025: 0.7p). Administrative costs fell to £1.773m from £2.418m, though the company noted increased spending on US sales support and IT infrastructure for Orion. R&D costs dropped to £212,000 from £410,000. Net cash used in operations was £4.47m for the half-year.
Cash stood at £2.51m at 31 March 2026, up from £1.39m at 30 September 2025, following a £7m Equity raise in November 2025. Development of EpiSwitch CiRT, the checkpoint-inhibitor response test, remains constrained: direct sales are restricted pending an application for inclusion in NCCN clinical guidelines for unresectable hepatocellular carcinoma, with additional data generation under way to support that application.
Key Numbers
- Revenue H1 (to 31 March 2026): £687k, up 17% from £587k a year earlier
- Operating loss: £4.68m (H1 2025: £5.88m)
- Loss for the period: £4.464m; loss per share 0.1p
- Cash at 31 March 2026: £2.51m; cash at 31 May 2026: £1.38m
- November 2025 equity raise: £7m
- Current Market Capitalisation : approximately £25.9m; share price around 8.3p
Growth Opportunities
The Orion agreement opens a new, potentially higher-margin revenue stream: charging third parties for access to OBD's data-processing capability rather than only selling finished diagnostic tests. Management says it is in commercial discussions with three large pharmaceutical companies regarding Orion, with further first agreements "now in negotiation." The MKCG deal offers a way to scale US sales coverage for EpiSwitch PSE without the fixed costs of an employed sales force, potentially accelerating uptake among urologists managing men with elevated PSA results — the test is cited as achieving 93% positive predictive value and 97% specificity. Success with NCCN guideline inclusion for CiRT would unlock a much larger market, and the company continues to seek non-dilutive grant funding for an EpiSwitch test for ME/CFS.
Risks Investors Should Know
The dominant risk is funding. The interim results state that cash stood at £1.38m as at 31 May 2026 and set out a requirement for additional funds by late August 2026. Management said that "as a significant non-dilutive funding transaction has not yet been secured," it is in discussions with advisers and key shareholders "to identify the most appropriate route to securing additional funding." The directors disclosed material uncertainties that "may cast significant doubt" on the group's ability to continue as a Going Concern , even while concluding it remains appropriate to prepare the accounts on that basis through to 30 June 2027. Beyond the funding gap, commercial traction for Orion and CiRT depends on deals not yet finalised and a guideline process with no guaranteed outcome, and the small market capitalisation raises the prospect of further dilution.
What to Watch Next
The most immediate catalyst is how OBD resolves its stated funding requirement before the end of August 2026 — whether through an equity raise, non-dilutive grant, licensing income or another structure. Beyond that, watch for confirmation of further Orion agreements, particularly with the pharmaceutical companies management says are in discussions, progress on the NCCN guideline application for CiRT, and early sales data from the MKCG partnership once representatives are deployed.
Outlook
Oxford BioDynamics (LSE:OBD) enters the second half of 2026 with tangible, if early, evidence that Orion and its US distribution strategy can generate paying interest beyond its existing test-sales base. That progress is real, but so is the funding cliff the company has itself flagged for late August. Whether the commercial momentum can be sustained will depend on how quickly the near-term cash need is resolved.






Please wait processing your request...